key: cord-0036126-worhjqzk
authors: Enright, Paul; Fragoso, Carlos A. Vaz
title: Asthma and COPD
date: 2012-06-26
journal: The Epidemiology of Aging
DOI: 10.1007/978-94-007-5061-6_24
sha: 14c0f5333f6f42585b9b00c7d884e203c7e0a145
doc_id: 36126
cord_uid: worhjqzk

Asthma and chronic obstructive pulmonary disease (COPD) are clinically important in older adults because like heart failure, they are common causes of chronic shortness of breath, which reduces the quality of life by limiting an individual’s activity. In developed countries, about 4% of older adults have been diagnosed with asthma and another 4% have been diagnosed with COPD, but the prevalence is doubled for each of these chronic respiratory diseases when objective tests are performed. COPD has become the fourth leading cause of death in some developed countries. COPD onset occurs almost exclusively in older age due to the cumulative effects of cigarette smoking in genetically-susceptible individuals. An upper respiratory viral infection commonly leads to the initial diagnosis of asthma at any age. About half of older adults with asthma have allergic triggers, compared to about 90% of asthmatic children. Exacerbations with dyspnea, wheezing and cough are the major morbidity of asthma and COPD, which limits activity, reduces quality of life and increases health care utilization and costs. In older adults as in younger adults, the most effective prevention for both asthma and COPD is smoking cessation.

Asthma, chronic obstructive pulmonary disease (COPD) and chronic heart failure are clinically important in older adults because they are common causes of chronic shortness of breath (dyspnea), which reduces quality of life by limiting activity. An older adult with any of these diseases is more likely to experience morbidity (exacerbations and hospitalization) and mortality. Asthma and COPD both cause airway narrowing, which can be detected by spirometry testing. While asthma can start during any decade of life, COPD only develops after decades of cigarette smoking and so is very rare before 40 years of age. It is important to distinguish between asthma, COPD and heart failure because the interventions differ; treatment for asthma is more successful and the prognosis is much better. About 20% of older adults with any one of these causes of dyspnea will also have one of the others (co-morbid conditions).

The de fi nitions of asthma and COPD are based on symptoms, self-reported diagnosis, and/or the testing of pulmonary function using spirometry. Asthma is de fi ned as episodic and reversible airways obstruction. COPD is de fi ned as chronic and irreversible airways obstruction. Other chronic conditions can also cause dyspnea. We de fi ne two of these here to distinguish them from asthma and COPD. The de fi nition of chronic bronchitis is based on a history of a chronic cough (productive of sputum or not) which has been present for at least 2 years. Epidemiologic studies use a standardized set of questions to de fi ne chronic bronchitis; no objective tests are needed. Emphysema is a term used to describe the irreversible destruction of lung tissue, which is detected using a breathing test called carbon monoxide diffusing capacity (DLCO) or by highresolution CT scans of the lungs that show reduced lung density or holes in the lungs (blebs or bullae). Overlap amongst the above chronic lung disease phenotypes does occur since decades of cigarette smoking can cause any one or all of them (asthma, chronic airway obstruction, chronic bronchitis and emphysema). spirometer mouthpiece as quickly as possible for at least 6 s. The volume of air forcefully exhaled during the fi rst second is called the forced expiratory volume (FEV1) and the total amount of air exhaled is called the forced vital capacity (FVC) (measured in liters). Healthy middle-aged adults can exhale about 75% of their air in the fi rst second, so the ratio of their FEV1/FVC is about 0.75. Smokers who have developed COPD have a permanently reduced capacity to exhale rapidly, so their FEV1 and their FEV1/FVC fall below the lower limit of the normal range (LLN).

Almost all clinical and epidemiological de fi nitions of COPD are based on a low FEV1/ FVC in a patient with COPD risk factors. However, the LLN for this ratio has been controversial. The pulmonary function standards committee of the American Thoracic Society [ 2 ] -the largest and most in fl uential pulmonary professional societyrecommends using the fi fth percentile LLNs from spirometry reference equations from the healthy, never-smoking subset of participants from the National Health and Nutrition Examination Survey (NHANES) III for use throughout North America [ 3 ] . The mean and LLN for the FEV1/FVC from this study (and from most studies of lung function in healthy population-based samples) decrease with aging. So the LLN for this ratio is about 0.75 for young adults and falls to about 0.60 for adults ³ 85 years of age ( Fig. 24.1 ). In the year 2000, an industry-sponsored, international group of key opinion leaders published and began extensive worldwide promotion of a COPD clinical practice guideline which de fi ned COPD as a FEV1/FVC ratio <0.70 (a fi xed threshold) after inhaling a fast-acting bronchodilator (post-BD). Many COPD guidelines developed for individual countries quickly adopted this de fi nition. However, compared to the use of an age-adjusted LLN, the use of this fi xed threshold to de fi ne COPD greatly increases the apparent prevalence of COPD in population-based samples of healthy older adults [ 4 ] . The vast majority of patients given a diagnosis of COPD in clinical settings present with symptoms; however, in population-based studies which included spirometry, half of adults with severe airway obstruction did not report respiratory symptoms. Therefore, epidemiologic studies with spirometry should base the COPD prevalence only on spirometry results.

Spirometers designed in the 1960s collected exhaled air in a container for measurement of the The values for females ( dashed lines ) are slightly higher than for men ( solid lines ) vital capacity ( Fig. 24 .2 ). Since tall people can exhale up to two gallons of air, these devices were bulky and heavy. During the 1990s, fl ow-sensing spirometers, many of which are hand-held and battery-powered, replaced the older devices. The American Thoracic Society provides standards for the accuracy of spirometers and spirometry procedures [ 2 ] .

One difference between asthma and COPD is that the airway obstruction of patients who have asthma is more likely to quickly respond to an inhaled bronchodilator medication (such as albuterol, also called salbutamol). Amongst individuals who have asthma, the majority of asthma is mild and intermittent. There is no airway obstruction between asthma exacerbations (which are usually triggered by an upper respiratory viral infection). Therefore, in epidemiological surveys, participants with mild asthma usually have normal spirometry tests (no airway obstruction). Those with moderate or poorly-controlled asthma have some degree of airway obstruction, but their lung function returns toward the normal range (due to increased FEV1) within 10 min post-BD ( Fig. 24.3 ). For those who report asthma-like symptoms, if their spirometry results improve into the normal range post-BD, COPD is ruled out and the probability of asthma is greatly increased.

In spirometry testing, CHF causes a small decrease in the FVC, but there is no airway obstruction [ 5 ] . CHF causes an increase in blood levels of B-type natriuretic peptide (BNP), while BNP levels are normal in patients who have asthma or COPD. Echocardiography shows left heart failure in CHF and right heart failure (i.e., cor pulmonale) in very severe COPD, but electrocardiography is normal in asthma (Table 24 .1 ).

The agency which funds the majority of pulmonary research in the United States (US), the Lung Division of the National Heart, Lung and Blood Institute, made asthma a high priority in the 1980s-1990s, so standardization of asthma de fi nitions was advanced for both reporting purposes and clinical practice guidelines. However, the emphasis was on the control of asthma in children. Although the US Centers for Disease Control and Prevention reported that the majority of asthma deaths occurred in older adults [ 6 ] , very little asthma research (observational or intervention) was done in this age group. Around the year 2000, the Lung Division shifted its major research funding and disease awareness programs to COPD, a disease almost exclusively of older adults. Still, controversy exists regarding the de fi nitions of asthma and COPD in older adults.

Older adults who have respiratory symptoms and airway obstruction that remains post-BD are An older woman blowing forcefully into a spirometer for 6 s. Due to COPD, her FEV1 is only 0.35 l (very severe airway obstruction) and she has required continuous oxygen therapy (2 l per minute to maintain her oxygen saturation above 90%) during the past decade. Note the nasal prongs which deliver the supplemental oxygen. She kindly gave us written permission to publish this 2012 photo of her classi fi ed by some studies as having asthma and by others as having COPD. Asthma has to be de fi ned on the basis of a physician diagnosis, but in the future, there should be some consideration of a reversibility of chronic obstruction. Some investigators use smoking status to classify the respiratory disease of those with post-BD airway obstruction (never smokers as having asthma or ever smokers as having COPD). Large epidemiological surveys of adults have demonstrated that about one-third of participants who have mild airway obstruction before inhaling a fast-acting bronchodilator (pre-BD) do not have airway obstruction post-BD. However, the majority of studies of chronic lung disease in adults do not take the time to perform post-BD spirometry (since it takes 15-20 min). A chronic cough is a very common feature in smokers who have developed COPD, so some studies wrongly include people with a chronic cough or chronic bronchitis under their de fi nition of COPD. However, even in adult smokers, there The bottom graph ( b ) shows traditional volume-time curves, from which the FEV1 and FVC are measured. The man's FEV1 was 1.5 l (from the pre-bronchodilator smaller curve); his FVC was 3.0 l; and his FEV1/FVC was only 0.50, con fi rming airway obstruction. The small x-marks indicate the predicted normal values. Ten minutes after inhaling a bronchodilator (albuterol), his FEV1 increased to 2.0 l (about 33% larger) and his FVC increased to about 3.7 l. If he had been a smoker with COPD, his bronchodilator response would have been much smaller (usually less than 0.25 l) are many other causes for a chronic cough (e.g., rhinosinusitis, gastro-esophageal re fl ux and asthma), so large COPD misclassi fi cation rates result when an objective measurement of airway obstruction is not performed.

The de fi nition of asthma for epidemiological surveys is less controversial than for COPD [ 7, 8 ] . For diagnosis of asthma, most studies of adults rely on participant recollection of a physician diagnosis of asthma, using a set of standardized questions. Study participants may also be asked to list their breathing medications or to bring them to a study visit. Objective measurements of the bronchial hyper-responsiveness (BHR) and eosinophilic airway in fl ammation of asthma are available [ 9 ] , but they have not come into widespread use due to the time needed to perform the BHR measurement (45-60 min for a methacholine or mannitol inhalation challenge test) and the expense of exhaled nitric oxide analyzers. Also, as discussed above, a spirometry test only detects moderate or poorly-controlled asthma.

A physician diagnosis of asthma underestimates the true prevalence of asthma because many people do not seek medical attention for what they consider to merely be "a cold that goes to my chest" [ 10 ] . However, the morbidity that is experienced by older adults who have recurrent, intermittent episodes of wheezing with shortness of breath but no diagnosis of asthma is similar to those who have a diagnosis of asthma.

As with other common chronic diseases for which expensive drugs are available, the exact de fi nition of the disease has large fi nancial implications (for the payors and sometimes for the individual patients). The market for medications that control airway obstruction greatly expands when de fi nitions for disease extend into the normal range and when clinical practice guidelines call for early detection and treatment of more mild disease. Currently, there is no evidence that early detection and treatment changes the natural history of COPD.

Two large population-based studies of adults from many countries have provided good estimates of the prevalence of COPD based on post-BD spirometry measurements [ 11, 12 ] (Fig. 24.4 ) .

The prevalence of COPD in the moderate range (50-90% predicted FEV1) in men and women ³ 60 years of age ranges from 3 to 6% (depending on the country). The prevalence of severe COPD (FEV1 below 50% predicted) is only about 1%. However, COPD is now the fourth leading cause of death in the US [ 13 ] .

Population-based samples of older adults have provided estimates of the prevalence of asthma in adults ³ 60 years of age [ 14, 15 ] . Using a large community-based cohort of individuals >65 years of age in the US, the CHS de fi ned de fi nite asthma as positive responses to the questions: "Has a physician ever told you that you have asthma?" and "Do you still have asthma?" Probable asthma was de fi ned as a history of wheezing in the past year associated with chest tightness or breathlessness. Excluding smokers and those with a diagnosis of congestive heart failure, 4% of individuals had de fi nite asthma and 4% had probable asthma [ 16 ] . Among current smokers, 11% had de fi nite asthma and 14% had probable asthma. The age of asthma onset was spread approximately evenly among decades, with 25% reporting onset before age 20 and 27% after age 60. In the US, the National Health Interview Survey asks questions regarding lifetime history of asthma, current asthma prevalence, and asthma attacks in the last 12 months [ 17 ] . For all age groups, asthma prevalence has been steadily increasing since 1980. For example, the prevalence of current asthma in those aged 65 and above rose from 6.0% in 2001 to 7.0% in 2004. For those ³ 65 years of age, asthma is consistently more prevalent in women than in men. In 2003, 3.3% of women over age 65 reported an asthma attack during the previous 12 months, compared to 1.7% of older men. The National Center for Health Statistics tracks data on physician encounters for asthma. Using this data, the National Ambulatory Care Survey reported that those ³ 65 years of age have the second-highest rate of outpatient of fi ce visits for asthma after preschool children, but do not have signi fi cantly different rates for emergency room visits compared to other adult age groups [ 18 ] . The 65+ age group accounts for a greater proportion of hospitalizations (23%) than the size of its population (13%) would indicate, and has higher asthma mortality rates than do young adults [ 6 ] .

Within the age range of 65-95, the risk of the clinical appearance of asthma or COPD does not increase appreciably with age. Allergic asthma commonly begins in childhood, but it can begin at any age. Older patients who have asthma often note the onset of asthma after age 60, usually associated with a serious cold or in fl uenza [ 16 ] . [ 11 ] ). No adjustment was made for predicted FEV1 for African race in Cape Town, South Africa or Lexington, Kentucky In contrast, age is a risk factor for COPD since it develops very slowly, with the onset of dyspnea upon exertion prompting a diagnosis in the fi fth or sixth decade of life. After age 85, the prevalence of COPD falls, probably due to mortality from other smoking-related diseases.

Aging is a cause of decreased lung function in older adults. Lung function grows with height in childhood and adolescence, reaches a peak in the 20s or early 30s then declines linearly throughout adulthood. FVC starts at 4-5 l in young adults (depending on height and gender) then declines by about one-third of a liter per decade. On average, the functional reserve of the lungs continues to slowly erode throughout older age, even in healthy individuals who have never smoked and had no measurable environmental exposures. The FEV1 declines at a somewhat faster rate than the FVC (largely due to a loss of lung tissue elasticity), so the FEV1/FVC also declines with aging. Age-related impairments in respiratory physiology become most problematic during maximal exercise or in an episode of acute lung injury (e.g., pneumonia), as well as in individuals who already have a reduced ventilatory reserve due to lung disease.

For a given exposure history (such as pack-years of smoking), women and men have a roughly equivalent risk of developing COPD [19] [20] [21] . Older women are more likely than older men to have asthma-like symptoms and to report dyspnea upon exertion (even after adjustment for other risk factors).

Studies have identi fi ed some racial differences in susceptibility to asthma and COPD. However, large projects have had only limited success in determining the exact set of genetic polymorphisms that are responsible for increased susceptibility for developing these chronic airway diseases [ 22 ] . African-Americans are more likely to have a genetic polymorphism that increases their risk of asthma (at all ages) and reduces the effectiveness of the long-acting bronchodilators which are commonly used to control asthma (inhaled beta-agonists). Amongst Hispanics, a greater percentage of African ancestry correlates with lower FVC and a greater risk of asthma and asthma severity [ 23 ] . On the other hand, African-American women are less susceptible to the risk that cigarette smoking will cause COPD [ 19 ] .

About one in fi ve people who begin smoking before age 20 will slowly develop COPD. About 90% of clinically-important COPD is caused by smoking.

The respiratory system has a very large functional reserve, so decades of slow loss in lung function usually occurs (as in COPD caused by cigarette smoking) before shortness of breath prompts the individual to seek medical attention [ 24 ] . Smoking also increases the risk of asthma (at all ages) and continued smoking makes asthma more dif fi cult to control because smoking reduces the effectiveness of inhaled corticosteroid therapy.

All of the common respiratory viruses have been associated with asthma and COPD exacerbations: respiratory syncytial virus (RSV), parain fl uenza viruses, coronaviruses, human metapneumovirus (hMPV) and rhinoviruses. Wheezing is a common symptom in older adults who are infected with any respiratory virus, particularly with RSV and hMPV, and 7 percent of adults who are hospitalized with RSV pneumonia will have a discharge diagnosis of asthma [ 25 ] .

Many risk factors for asthma in young and middle-aged adults have been identi fi ed. Most remain as risk factors for asthma in older adults. In the CHS cohort, 58% of older-adult asthmatics reported the most common trigger of an asthma exacerbation to be an upper respiratory viral infection (upper respiratory infection, common cold or in fl uenza), while 30% reported that contact with animals caused their asthma to worsen. Two-thirds reported seasonal worsening.

About 50% of older adults with asthma have allergic triggers, compared to about 90% of asthmatic children. The Epidemiology and Natural History of Asthma (TENOR) study compared the natural history of asthma in younger and older patients [ 26 ] . The older patients had lower total immunoglobulin E (IgE) levels, fewer positive skin prick tests and less concomitant allergic rhinitis or atopic dermatitis. There is also evidence for an age-related decline in skin-prick test responses to allergens; however, older adults who have greater levels of IgE remain more likely to have allergic rhinitis and asthma [ 27 ] .

A few epidemiologic studies have suggested an association between short-term worsening of outdoor air pollution and emergency department or hospital admissions for asthma in older adults [ 28 ] . Decades of exposure to severe outdoor air pollution may increase the risk of at least mild COPD in older ages [ 29 ] . Like the skin, the lungs have a very large surface area which is directly exposed to the environment. In fl ammatory responses to these exposures usually promote long-term health, but they can also cause long-term damage in a susceptible subset of individuals, damage which often accumulates decadeby-decade. Occupational exposures to inhaled dusts, fumes, smoke and chemicals increase the risk of chronic airway obstruction which persists into older age [ 30 ] . Decades of exposure to second-hand smoke, or to smoke from cooking with biomass fuels in developing countries, increases the risk of chronic bronchitis [ 31 ] . It remains unknown whether these environmental exposures also cause clinically-important COPD because almost all studies used pre-BD FEV1/FVC <0.70 to de fi ne COPD, which caused high false-positive rates for airway obstruction.

Older adults with asthma or COPD frequently have respiratory symptoms such as chronic cough, phlegm and wheezing, all caused by their chronic airway in fl ammation [ 32 ] . Reduced lung function causes shortness of breath which limits their activity, reduces the quality of their lives and prompts them to utilize health care during exacerbations (visit emergency departments, sometimes leading to hospitalizations) [ 33 ] . This morbidity, along with the drugs prescribed for their dyspnea, is expensive [34] [35] [36] . Dyspnea is the most distressing feature of chronic lung disease and is a leading cause of disability and healthcare utilization [ 37 ] . In the CHS cohort, dyspnea upon exertion was 1.6-fold more likely to be present in patients diagnosed with asthma than in those without the diagnosis [ 16 ] . Asthma had a signi fi cant impact on quality of life, with 35% of older adults who have de fi nite or probable asthma reporting a fair or poor health status compared to 17% of older adults who do not have asthma. Depression, restless sleep and daytime sleepiness were substantially more common in those with asthma.

Dyspnea may be considered an imbalance between ventilatory capacity and ventilatory demand. Increased ventilatory demand is commonly caused by comorbid conditions such as heart failure, anemia, obesity and peripheral vascular disease. The ability of the chest wall to expand easily is reduced by osteoporosis (vertebral compression, kyphosis and scoliosis) and osteoarthritis.

Very severe COPD and CHF (but not asthma) commonly cause skeletal muscle weakness (sarcopenia). Respiratory muscle weakness is a major factor that causes respiratory failure in COPD and pneumonia. The strength of the diaphragm, which is the primary breathing muscle, can be measured by a simple pressure meter. Maximal inspiratory pressure (MIP) ranges from 20 (very low) to 150 cm of water (normal), and is the best index of respiratory muscle strength [ 38 ] . MIP is an independent predictor of all-cause, cardiovascular and respiratory death in older adults [ 39 ] .

The most effective primary and secondary prevention for asthma and COPD after age 65 is the same as for middle age: smoking cessation. About half of older adults who have asthma and about one-third of those who have COPD are current smokers. Smoking cessation, both in middle age and older ages, is the only intervention that has been proven to slow the progression of COPD (thereby altering the natural history of the disease). Smoking cessation has been proven to make asthma respond better to inhaled corticosteroids, thus improving asthma control, and has been proven to prolong the life of those with COPD. The chronic cough and phlegm production of COPD will improve with successful smoking cessation, but the loss of lung function and emphysema are not reversible. The cough may get worse for a few weeks, but the degree of dyspnea on exertion tends to remain.

In fl uenza and pneumococcal vaccinations reduce asthma and COPD exacerbation rates [ 40 ] . It is likely that avoiding exposure to young children who have upper respiratory infections also reduces the risk of exacerbations, but no clinical trials have studied the bene fi t of avoiding exposure to these young children.

Another prevention method for asthma and COPD is avoiding the inhalation of respiratory irritants (e.g., smoke, fumes, dusts chemicals), which cause airway in fl ammation that persists for several hours after inhalation. This temporary in fl ammation increases coughing and phlegm from the lower airways. It also causes nasal congestion, leading to mouth breathing which bypasses the heating, humidi fi cation and dust removal of nasal passages which naturally protects the lower airways (in the lungs).

Asthma, COPD and heart failure are clinically important in older adults because they are common causes of dyspnea, which reduces the quality of life by limiting activity. In developed countries, about 4% of older adults have been diagnosed with asthma and another 4% with COPD. Epidemiologic studies use standardized questionnaires to determine the presence of asthma and post-BD spirometry to detect and verify COPD. An upper respiratory viral infection commonly leads to the initial diagnosis of asthma in older adults. About 90% of COPD is due to the cumulative effects of cigarette smoking in genetically-susceptible individuals. About half of older adults with asthma have allergic triggers. Periodic exacerbations with dyspnea, wheezing and cough are the major morbidity of asthma and COPD. Both conditions are associated with a higher risk of death. In older adults, the most effective prevention for both asthma and COPD is smoking cessation.

How to assess pulmonary function in older adults

Standardisation of spirometry

Reference ranges for spirometry across all ages: a new approach

Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassi fi cation of airway obstruction

Heart failure and COPD: diagnostic pitfalls and epidemiology

Increasing U.S. asthma mortality rates: who is really dying?

National asthma education and prevention program: expert panel report 3-guidelines for the diagnosis and management of asthma

De fi ning asthma in epidemiological studies

Airway hyper-responsiveness in the elderly: prevalence and clinical implications

Aging and disability affect misdiagnosis of COPD in elderly asthmatics: the SARA study

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

Chronic obstructive pulmonary disease in fi ve Latin American cities (the PLATINO study): a prevalence study

Trends in the leading causes of death in the United States

Asthma in the elderly: current knowledge and future directions

Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey

Underdiagnosis and undertreatment of asthma in the elderly

National surveillance for asthma-United States

National ambulatory medical care survey: 1999 summary

Race and gender differences in the effects of smoking on lung function

Chronic obstructive pulmonary disease in men and women: myths and reality

Sex-related differences in COPD in fi ve Latin American cities: the PLATINO study

Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research

Genetic ancestry in lung-function predictions

Smoking and lung function in elderly men and women: the Cardiovascular Health Study

Role of viral infections in asthma and chronic obstructive pulmonary disease

Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study

Allergy and immunology of the aging lung

Induction of asthma and the environment: what we know and need to know

Long-term particulate and other air pollutants and lung function in nonsmokers

Occupation in chronic obstructive pulmonary disease and chronic bronchitis: an update

Is exposure to biomass smoke the biggest risk factor for COPD globally?

A self-complete measure of health status for chronic air fl ow limitation. The St. George's Respiratory Questionnaire

Epidemiology and costs of COPD

Incidence and outcomes of asthma in the elderly. A population-based study in

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare advantage population

Asthma costs and utilization in a managed care organization

Dyspnea: mechanisms, assessment, and management. A consensus statement

Correlates of respiratory muscle strength, and maximal respiratory pressure reference values in the elderly

Respiratory muscle strength and the risk of incident cardiovascular events

Mortality bene fi ts of in fl uenza vaccination in elderly people: an ongoing controversy